Cartalax is short synthetic peptide marketed as a cartilage bioregulator. Researchers examine it in relation to chondrocyte, extracellular-matrix and cartilage-ageing models.

Researchers study whether it can affect cartilage cells and the material surrounding them. It is not a proven treatment for joints or cartilage damage.

Proposed tissue-specific gene-regulatory effects remain preclinical and are not tied to a validated clinical receptor pathway.

Very limited independently replicated research and no established therapeutic indication.

No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.